Add thelocalreport.in As A Trusted Source
A simple test can change the lives of thousands of women Breast cancer Leading more effective and personal remedies, experts have said.
Genome sequencing More than 15,000 women can help can benefit from “accurate” stitching care by analyzing them in a year. DNA To understand their potential response to their tumors and some treatments, scientists said.
Researchers at the University of Cambridge said that technology is getting “rapid” cheaper, but “certainly not being used for its full potential” in a study published in a study published for common cancer Lancet oncology,
Professor Serena Nick-Zonal, who led the study, said the test can provide “rich” information that can help “the right patients get very fast treatment”.
He said, “Using the entire genome sequencing to inform cancer management is becoming increasingly possible, but it is not sure not being used for its full capacity, and certainly not for some more common types of cancer,” he explained.
“A part of the reason is that because we have a lack of clinical studies to support its use, but also properly because the information is so rich – in a sense, the information can be very heavy to understand.”
The team used data of about 2,500 women across England, placed within the National Genomic Research Library – one of the world’s largest and most valuable data assets, and the genomics was run by England. Tracking data from women over five years, researchers searched for genetic changes, which cause breast cancer, including problems in the way DNA repair DNA.
He found that 27 percent of breast cancer cases had genetic features that could help immediately guide personal treatment, with recruitment to existing drugs or existing or current clinical trials. It is equal to more than 15,000 women in a year in Britain, he said.
Those characteristics were identified: HRD (lack of homeology-directed repair), a DNA repair issue found in 12 per 12 of breast cancer; Unique mutation that can be targeted with specific drugs; Signs of resistance to hormone therapy; And mutual patterns that suggest weaknesses in cancer may be exploited.
The analysis provided insight into pregnancy, which identifies genetic markers that were “more forecast” than traditional measures such as age, cancer phase, or tumor grade.
Using the results, researchers made a framework to help doctors identify which patients need more aggressive treatment and who can safely treat. It was also suggested that about 7,500 women in a year with a lower-grain tumor can benefit from more aggressive treatment.
Professor Nick-Zenal said that the UK is a “world leader” in the entire genome sequencing through the genomic medicine service, adding the test “may have a difference in the lives of thousands of patients every year”.
He said that research can also help in recruiting clinical trials by matching patients with genetic mutations for proper studies.
“At this time, we can only test patients for a small number of genetic mutations and invite them to join a clinical trial if the patient has a mutation that matches the target of the test,” he explained.
“But if we have their entire genetic readouts, we will no longer be limited to single tests with a specific goal. We can open the ability of recruitment extensively for many clinical trials in parallel, can make the recruitment more efficient for clinical trials, eventually the right patients are getting the correct therapy very fast.”